BridgeMD
New treatment option for Exposure to Man-made Visible Light
Official title Peripheral Blood Flow Responses to Electromagnetic Energy
ClinicalTrials.gov ID: NCT02370199
What this study is testing
What is octafluropropane?
octafluropropane is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for exposure to man-made visible light.
Also referred to as Definity.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study evaluates 670 nm energy in the form of red light to stimulate blood flow changes in healthy adults. All participants will receive red light to their leg.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 59. Healthy volunteers may be eligible.
You may be able to join if
- Participants will be healthy people over the age of 18.
- Men and women will be recruited for participation.
- All ethnicities will be included in this study.
You likely can't join if
- Exclusionary criteria include:
- age under 18 years and those over 60 years of age,
- those who are unable to understand the consent process,
- those who cannot read or speak English,
- a history of cancer,
- peripheral artery disease,
See the full eligibility criteria
- Participants will be healthy people over the age of 18.
- Men and women will be recruited for participation.
- All ethnicities will be included in this study.
- Exclusionary criteria include:
- age under 18 years and those over 60 years of age,
- those who are unable to understand the consent process,
- those who cannot read or speak English,
- a history of cancer,
- peripheral artery disease,
- diabetes mellitus,
- active pregnancy,
- hypersensitivity to perflutren contrast agents,
- pulmonary hypertension,
- chronic kidney disease,
- active tobacco or drug use,
- blood pressure over 160/90, BMI\>30,
- sickle cell disease, or
- history of intracardiac shunt. Additional exclusion criteria include:
- a history of coronary artery disease,
- heart failure,
- the presence of an implanted defibrillator or pacemaker,
- a history of heart murmur or rhythm disorder (atrial fibrillation, atrial tachycardia, or ventricular tachycardia),
- neurological diseases such as stroke, and
- any uncontrolled medical conditions.
The study team makes the final eligibility decision.
Where it's taking place
- Milwaukee, Wisconsin, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 59 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Milwaukee, Wisconsin, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.